A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2018
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2017 Status changed from recruiting to completed.
- 25 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.